Literature DB >> 28887153

The Eya phosphatase: Its unique role in cancer.

Hengbo Zhou1, Lingdi Zhang2, Rebecca L Vartuli3, Heide L Ford1, Rui Zhao4.   

Abstract

The Eya proteins were originally identified as essential transcriptional co-activators of the Six family of homeoproteins. Subsequently, the highly conserved C-terminal domains of the Eya proteins were discovered to act as a Mg2+-dependent Tyr phosphatases, making Eyas the first transcriptional activators to harbor intrinsic phosphatase activity. Only two direct targets of the Eya Tyr phosphatase have been identified: H2AX, whose dephosphorylation directs cells to the DNA repair instead of the apoptotic pathway upon DNA damage, and ERβ, whose dephosphorylation inhibits its anti-tumor transcriptional activity. The Eya Tyr phosphatase mediates breast cancer cell transformation, migration, invasion, as well as metastasis, through targets not yet identified. Intriguingly, the N-terminal domain of Eya contains a separate Ser/Thr phosphatase activity implicated in innate immunity and in regulating c-Myc stability. Thus, Eya proteins are highly complex, containing two separable phosphatase domains and a transcriptional activation domain, thereby influencing tumor progression through multiple mechanisms.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Eya; Inhibitor; Phosphatase; Ser/Thr phosphatase; Tyr phosphatase

Mesh:

Substances:

Year:  2017        PMID: 28887153      PMCID: PMC5808901          DOI: 10.1016/j.biocel.2017.09.001

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  89 in total

1.  Regulation of the innate immune response by threonine-phosphatase of Eyes absent.

Authors:  Yasutaka Okabe; Teruyuki Sano; Shigekazu Nagata
Journal:  Nature       Date:  2009-06-28       Impact factor: 49.962

2.  Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.

Authors:  Dipak Datta; Jesse A Flaxenburg; Sreenivas Laxmanan; Christopher Geehan; Martin Grimm; Ana Maria Waaga-Gasser; David M Briscoe; Soumitro Pal
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

3.  Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.

Authors:  Hirotaka Sato; Sadatsugu Minei; Takahiko Hachiya; Toshio Yoshida; Yukie Takimoto
Journal:  Int J Urol       Date:  2006-06       Impact factor: 3.369

4.  Breast cancer cell-derived cytokines, macrophages and cell adhesion: implications for metastasis.

Authors:  Christine Eichbaum; Anne-Sophie Meyer; Ni Wang; Esther Bischofs; Andrea Steinborn; Thomas Bruckner; Pnina Brodt; Christof Sohn; Michael H R Eichbaum
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

5.  Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.

Authors:  Kian Behbakht; Lubna Qamar; Carrie S Aldridge; Ricardo D Coletta; Susan A Davidson; Andrew Thorburn; Heide L Ford
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

6.  Six1 and Six4 homeoproteins are required for Pax3 and Mrf expression during myogenesis in the mouse embryo.

Authors:  Raphaelle Grifone; Josiane Demignon; Christophe Houbron; Evelyne Souil; Claire Niro; Mary J Seller; Ghislaine Hamard; Pascal Maire
Journal:  Development       Date:  2005-03-23       Impact factor: 6.868

7.  Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer.

Authors:  Lubna Qamar; Erin Deitsch; Aaron N Patrick; Miriam D Post; Monique A Spillman; Ritsuko Iwanaga; Andrew Thorburn; Heide L Ford; Kian Behbakht
Journal:  Gynecol Oncol       Date:  2012-02-12       Impact factor: 5.482

Review 8.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

9.  A phosphotyrosine switch determines the antitumor activity of ERβ.

Authors:  Bin Yuan; Long Cheng; Huai-Chin Chiang; Xiaojie Xu; Yongjian Han; Hang Su; Lingxue Wang; Bo Zhang; Jing Lin; Xiaobing Li; Xiangyang Xie; Tao Wang; Rajeshwar R Tekmal; Tyler J Curiel; Zhi-Min Yuan; Richard Elledge; Yanfen Hu; Qinong Ye; Rong Li
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

10.  Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma.

Authors:  K T Ng; K Man; C K Sun; T K Lee; R T Poon; C-M Lo; S-T Fan
Journal:  Br J Cancer       Date:  2006-09-26       Impact factor: 7.640

View more
  10 in total

1.  Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase.

Authors:  Jothi Anantharajan; Nithya Baburajendran; Grace Lin; Yong Yao Loh; Weijun Xu; Nur Huda Binte Ahmad; Shuang Liu; Anna E Jansson; John Wee Liang Kuan; Elizabeth Yihui Ng; Yee Khoon Yeo; Alvin W Hung; Joma Joy; Jeffrey Hill; Heide L Ford; Rui Zhao; Thomas H Keller; CongBao Kang
Journal:  Protein Sci       Date:  2021-11-18       Impact factor: 6.725

Review 2.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

3.  Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.

Authors:  Jothi Anantharajan; Hengbo Zhou; Lingdi Zhang; Taylor Hotz; Melanie Y Vincent; Melanie A Blevins; Anna E Jansson; John Wee Liang Kuan; Elizabeth Yihui Ng; Yee Khoon Yeo; Nithya Baburajendran; Grace Lin; Alvin W Hung; Joma Joy; Samarjit Patnaik; Juan Marugan; Pratyaydipta Rudra; Debashis Ghosh; Jeffrey Hill; Thomas H Keller; Rui Zhao; Heide L Ford; CongBao Kang
Journal:  Mol Cancer Ther       Date:  2019-07-08       Impact factor: 6.261

4.  Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4.

Authors:  Soledad A Camolotto; Veronika K Belova; Luke Torre-Healy; Jeffery M Vahrenkamp; Kristofer C Berrett; Hannah Conway; Jill Shea; Chris Stubben; Richard Moffitt; Jason Gertz; Eric L Snyder
Journal:  Gut       Date:  2020-08-21       Impact factor: 23.059

5.  GWAS of allometric body-shape indices in UK Biobank identifies loci suggesting associations with morphogenesis, organogenesis, adrenal cell renewal and cancer.

Authors:  Sofia Christakoudi; Evangelos Evangelou; Elio Riboli; Konstantinos K Tsilidis
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.996

6.  WDR1 is a novel EYA3 substrate and its dephosphorylation induces modifications of the cellular actin cytoskeleton.

Authors:  Mihaela Mentel; Aura E Ionescu; Ioana Puscalau-Girtu; Martin S Helm; Rodica A Badea; Silvio O Rizzoli; Stefan E Szedlacsek
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

Review 7.  Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery.

Authors:  Qingxin Li; CongBao Kang
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

Review 8.  Phosphatases in toll-like receptors signaling: the unfairly-forgotten.

Authors:  Valérie Lannoy; Anthony Côté-Biron; Claude Asselin; Nathalie Rivard
Journal:  Cell Commun Signal       Date:  2021-01-25       Impact factor: 5.712

Review 9.  Novel Methylation Biomarkers for Colorectal Cancer Prognosis.

Authors:  Alvaro Gutierrez; Hannah Demond; Priscilla Brebi; Carmen Gloria Ili
Journal:  Biomolecules       Date:  2021-11-19

10.  Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe.

Authors:  Guoxin Zhang; Zhen Dong; Ryan C Gimple; Arthur Wolin; Qiulian Wu; Zhixin Qiu; Lisa M Wood; Jia Z Shen; Li Jiang; Linjie Zhao; Deguan Lv; Briana C Prager; Leo J Y Kim; Xiuxing Wang; Lingdi Zhang; Ryan L Anderson; Jeffrey K Moore; Shideng Bao; Thomas H Keller; Grace Lin; Congbao Kang; Petra Hamerlik; Rui Zhao; Heide L Ford; Jeremy N Rich
Journal:  J Exp Med       Date:  2021-10-07       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.